Introduction: This study aimed to identify issues and concerns involved in a community-based activity and to identify requirements for supporting its continuation. Methods: Between September and November 2021, interviews were conducted with 12 volunteer residents who manage a community-based activity. Deductive content analysis was used to analyze the data. Yrjö Engeström's activity system model was used as the analytical framework. Results: Within the components of the activity system, the following "contradictions" were identified: supporters were anxious to continue their activities, the number of new participants in the community-based activity was not increasing, and human relationship difficulties constituted a regional characteristic. Among the components, the following "contradictions" were identified: many older adults were unable to participate in the community-based activity because of age- or health-related reasons, many older adults worked, and there were various other activities that did not result in subsequent participation in the community-based activity. Conclusion: The model also identified the need to consider visualization of the benefits of the community-based activity, comprehensive publicity activities involving residents, creating a system that allows people of all health levels to participate, and ongoing support for health promotion for the younger generation with anticipation of old age.

Background: Arbekacin (ABK) is an aminoglycoside that exhibits anti-methicillin-resistant Staphylococcus aureus (MRSA) and anti-Pseudomonas aeruginosa activities. Therefore, for patients with febrile neutropenia (FN) and concurrent pneumonia suspected to be caused by MRSA, ABK may be sufficiently effective even as a single agent. Materials and Methods: Patients with hematologic malignancies treated with ABK who met the following criteria were included: 1) fever during neutropenia or functional neutropenia, 2) FN complicated by pneumonia, and 3) possible infection by antimicrobial-resistant Grampositive cocci. Results: This study encompassed 22 episodes involving 19 patients, of which, 15 (68.2%) were successfully treated with ABK. Of the nine episodes showing inadequate response to other anti-MRSA drugs, eight were successfully treated with ABK. Grade 2 or worse adverse events included acute kidney injury (13.6%) and increased transaminase levels (9.1%). Conclusion The present study demonstrated that ABK is effective and safe in patients with FN and concurrent pneumonia caused by antimicrobial-resistant Gram-positive cocci. ABK may also be effective in patients who are unresponsive to other anti-MRSA drugs. Therefore, ABK may be beneficial in the treatment of pneumonia caused by antimicrobial-resistant Gram-positive cocci in patients with FN.